DMAC - DiaMedica Therapeutics Inc.
| Previous close | 2.6000 |
| Open | 2.6000 |
| Bid | 2.7000 x 800 |
| Ask | 2.9200 x 800 |
| Day's range | 2.5400 - 2.7400 |
| 52-week range | 1.1200 - 3.1700 |
| Volume | |
| Avg. volume | 49,053 |
| Market cap | 72.721M |
| Beta (5Y monthly) | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5500 |
| Earnings date | 08 Aug 2023 - 14 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
Business WireDiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
MINNEAPOLIS, May 30, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
Business WireDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
MINNEAPOLIS, May 15, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2023. Management will host a conference call Tuesday, May 16, 2023, at 7:00AM Central Daylight Time/8:00AM Eastern Daylight Time to discuss its business update and first quarter 2023 financial results.
Business WireDiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
MINNEAPOLIS, May 08, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th. DiaMedica will host a live conference call on Tuesday, May 16th at 7:00 AM Central Time to provide a business update and discuss financial results.
Business WireDiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer
MINNEAPOLIS, April 11, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO). In this position, he will lead business development, including financing and partnering strategies, and acceleration of prioritized development programs, as well as other business operations.
Business WireDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
MINNEAPOLIS, March 28, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the year ended December 31, 2022. Management will host a conference call Wednesday, March 29, 2023, at 7:00AM Central Daylight Time/8:00AM Eastern Daylight Time to discuss its business update and full year 2022 financial results.
Business WireDiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
MINNEAPOLIS, March 20, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th. DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results.
- Business Wire
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
MINNEAPOLIS, March 13, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will present a corporate overview at the virtual Oppenheimer 33rd Annual Healthcare Conference, which will take place March 13th – 15th, 2023.
Business WireDiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
MINNEAPOLIS, March 06, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs.
Business WireDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
MINNEAPOLIS, November 09, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended September 30, 2022.
Business WireDiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
MINNEAPOLIS, November 07, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.
ZacksWhat Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Business WireDiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
MINNEAPOLIS, October 31, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 – 10, 2022 in Rancho Palos Verdes, California.
Business WireDiaMedica Therapeutics Provides Update on ReMEDy2 Trial
MINNEAPOLIS, October 26, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on its ReMEDy2 Phase 2/3 trial for the treatment of acute ischemic stroke (AIS). The FDA stated it is maintaining its clinical hold at this time and that a
Business WireDiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
MINNEAPOLIS, September 14, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations. Ms. Daves, a recognized leader in managing global clinical studies, has significant experience in all phases of clinical development and will complement DiaMe
Business WireDiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
MINNEAPOLIS, September 06, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022. Management will conduct one-on-one meetings with investors during the conference.
Business WireDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
MINNEAPOLIS, August 10, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended June 30, 2022. DiaMedica will host a conference call on Thursday, August 11, 2022, at 8:00AM Eastern Time / 7:00AM Central Time, to discuss its business update and second quarter financial results.
- Business Wire
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
MINNEAPOLIS, August 04, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second quarter 2022 financial results will be released after the markets close on Wednesday, August 10th. DiaMedica will host a live conference call on Thursday, August 11th at 7:00 AM Central Time to provide a business update and discuss financial results.
- Business Wire
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
MINNEAPOLIS, August 01, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022.
Business WireDiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
MINNEAPOLIS, July 06, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company’s Phase 2/3 ReMEDy2 trial studying the use of the Company’s product candidate, DM199, to treat acute ischemic stroke (AIS) patients. The clinical hold was initiated following the Company’s pa